Report of Foreign Issuer (6-k)
October 02 2020 - 06:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or
15d-16
Under the Securities Exchange Act of 1934
For the Month of October, 2020
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jeusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Exhibit Index
This Report on Form 6-K is
hereby incorporated by reference into the Company’s Registration
Statement on Form F-3 (Registration No. 333-240189) and
its Registration Statement on Form S-8 (Registration
No. 333-239344).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd. |
|
|
|
Date:
October 1, 2020 |
By: |
/s/ Ron Babecoff |
|
|
Ron
Babecoff |
|
|
Chief
Executive Officer |
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Dec 2020 to Jan 2021
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Jan 2020 to Jan 2021